The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

That's because the primary progressive symptoms tend to be caused by neurons in the CNS physically breaking down, as opposed to the inflammation seen in relapsing MS. Currently, ocrelizumab is the ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS ... ocrelizumab in adults with relapsing multiple sclerosis (MS) failed to meet its ...

Further information Decision makers have concluded that this technology will not progress as a potential technology appraisal or a highly specialised technology. This decision follows consideration of ...

Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab ... B-cell therapy approved for relapsing MS and primary progressive MS and after more than ten years ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in ...

Tolebrutinib is currently being investigated in patients with primary progressive MS in the phase 3 PERSEUS trial (ClinicalTrials.gov Identifier: NCT04458051). 1.Tolebrutinib regulatory submission ...

Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster ... The treatment for relapsing remitting and primary progressive MS is taken as an intravenous infusion ...

Primary progressive MS (PPMS) is a debilitating form of the ... have had a life-threatening administration reaction to ocrelizumab. have had a life-threatening allergic reaction to ocrelizumab ...

Roche’s star multiple sclerosis (MS) drug Ocrevus (ocrelizumab ... disease-modifying drug for people in the EU with early primary progressive MS. It has also been approved in relapsing forms ...